Understand the source comparison
Peptides Help with Lyme Disease — Comparison of Immune-Modulating Protocols
Thymosin Alpha-1 (T 1) Enhances Treg differentiation; upregulates TLR signalling 1.6mg subcutaneous twice weekly, 12–16 weeks Moderate (Phase III trials in viral infections; no Lyme-specific RCT) Strongest evidence for immune recovery in chronic inflammatory s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1 (Tα1)
- Enhances Treg differentiation; upregulates TLR signalling
- 1.6mg subcutaneous twice weekly, 12–16 weeks
- Moderate (Phase III trials in viral infections; no Lyme-specific RCT)
- Strongest evidence for immune recovery in chronic inflammatory states; directly addresses Th1/Th2 imbalance seen in PTLDS
- BPC-157
- Modulates VEGF and nitric oxide; promotes tissue repair
- 250–500mcg daily subcutaneous or oral, 8–12 weeks
- Low (animal models + case reports only)
- Promising for joint and neural symptom relief; mechanism fits PTLDS pathology but lacks rigorous human trials
- Thymosin Beta-4 (Tβ4)
- Actin-sequestering peptide; promotes cell migration and angiogenesis
- 5–10mg subcutaneous weekly, variable duration
- Low (mostly wound healing and cardiac studies)
- May support tissue repair in chronic Lyme arthritis; limited immune-specific data
- KPV (Lysine-Proline-Valine)
- Inhibits NF-κB pathway; reduces inflammatory cytokines
- 500mcg–1mg daily subcutaneous, 4–8 weeks
- Low (preclinical + anecdotal)
- Anti-inflammatory signal fits PTLDS profile; human data insufficient to assess efficacy